WO2025219976 - PEPTIDES AND FRAGMENTS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
National phase entry is expected:
Publication Number
WO/2025/219976
Publication Date
23.10.2025
International Application No.
PCT/IB2025/054128
International Filing Date
18.04.2025
Title **
[English]
PEPTIDES AND FRAGMENTS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
[French]
PEPTIDES ET FRAGMENTS POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES MÉTABOLIQUES ASSOCIÉES
Applicants **
BETAVIVE LTD.
Inventors
PALTI, Yoram
ZURI, Dotan
Priority Data
63/636,270
19.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2833 | |
| EPO | Filing, Examination, Granting | 14852 | |
| Japan | Filing, Examination, Granting | 2433 | |
| South Korea | Filing, Examination, Granting | 2637 | |
| USA | Filing, Examination, Granting | 5990 |
Total:
28,745
Contact Us
Abstract[English]
The disclosure provides for peptides, fragments, compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering peptides, fragments, or a variant thereof to the subject for treating diabetes and diseases related to diabetes. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof, IGF-2 peptides, and IGF-2 fragments are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.[French]
La présente divulgation concerne des peptides, des fragments, des composés, des compositions et leurs méthodes d'utilisation pour le traitement du diabète (p. ex. du diabète de type 1 ou de type 2). Dans certains aspects, les méthodes comprennent l'administration de peptides, de fragments ou d'un variant de ceux-ci au sujet pour le traitement du diabète et de maladies associées au diabète. Dans d'autres aspects, des composés, des compositions et des méthodes comprenant IGF-2 ou des variants de celui-ci, des peptides d'IGF-2 et des fragments d'IGF-2 sont utilisés pour traiter un trouble chez un patient en ayant besoin, tel que le diabète de type 1 ou de type 2.